The Current State of Vaccine Development for Ocular HSV-1 Infection
about
A STING-dependent innate-sensing pathway mediates resistance to corneal HSV-1 infection via upregulation of the antiviral effector tetherinA Highly Efficacious Herpes Simplex Virus 1 Vaccine Blocks Viral Pathogenesis and Prevents Corneal Immunopathology via Humoral ImmunityThe Neonatal Fc Receptor and Complement Fixation Facilitate Prophylactic Vaccine-Mediated Humoral Protection against Viral Infection in the Ocular Mucosa.Impact of Type I Interferon on the Safety and Immunogenicity of an Experimental Live-Attenuated Herpes Simplex Virus 1 Vaccine in Mice.Herpesvirus-Associated Lymphadenitis Distorts Fibroblastic Reticular Cell Microarchitecture and Attenuates CD8 T Cell Responses to Neurotropic Infection in Mice Lacking the STING-IFNα/β Defense Pathways.Reply to "Highly Efficacious Novel Vaccine, Humoral Immunity, and Ocular Herpes Simplex Virus 1: Reality or Myth?"
P2860
The Current State of Vaccine Development for Ocular HSV-1 Infection
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
The Current State of Vaccine Development for Ocular HSV-1 Infection
@ast
The Current State of Vaccine Development for Ocular HSV-1 Infection
@en
type
label
The Current State of Vaccine Development for Ocular HSV-1 Infection
@ast
The Current State of Vaccine Development for Ocular HSV-1 Infection
@en
prefLabel
The Current State of Vaccine Development for Ocular HSV-1 Infection
@ast
The Current State of Vaccine Development for Ocular HSV-1 Infection
@en
P2860
P1476
The Current State of Vaccine Development for Ocular HSV-1 Infection
@en
P2093
P2860
P304
P356
10.1586/17469899.2015.1004315
P577
2015-04-01T00:00:00Z